Vanguard Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.38B | Sell |
9,700,301
-6,258
| -0.1% | -$907K | 0.02% | 595 |
|
|
2025
Q3 | $1.36B | Sell |
9,706,559
-100,507
| -1% | -$13.6M | 0.02% | 589 |
|
|
2025
Q2 | $1.23B | Sell |
9,807,066
-134,821
| -1% | -$15.5M | 0.02% | 604 |
|
|
2025
Q1 | $1.1B | Sell |
9,941,887
-177,754
| -2% | -$22.5M | 0.02% | 611 |
|
|
2024
Q4 | $1.38B | Buy |
10,119,641
+122,681
| +1% | +$15.2M | 0.02% | 564 |
|
|
2024
Q3 | $1.15B | Sell |
9,996,960
-59,486
| -0.6% | -$8.15M | 0.02% | 613 |
|
|
2024
Q2 | $1.38B | Buy |
10,056,446
+125,520
| +1% | +$17.2M | 0.03% | 540 |
|
|
2024
Q1 | $1.37B | Buy |
9,930,926
+220,598
| +2% | +$30.1M | 0.03% | 558 |
|
|
2023
Q4 | $1.28B | Buy |
9,710,328
+150,485
| +2% | +$17.3M | 0.03% | 557 |
|
|
2023
Q3 | $1.08B | Sell |
9,559,843
-10,875
| -0.1% | -$1.15M | 0.03% | 574 |
|
|
2023
Q2 | $903M | Sell |
9,570,718
-26,814
| -0.3% | -$2.62M | 0.02% | 649 |
|
|
2023
Q1 | $971M | Buy |
9,597,532
+257,237
| +3% | +$26.8M | 0.02% | 601 |
|
|
2022
Q4 | $1.12B | Buy |
9,340,295
+339,332
| +4% | +$39.7M | 0.03% | 541 |
|
|
2022
Q3 | $956M | Buy |
9,000,963
+96,489
| +1% | +$9.79M | 0.03% | 575 |
|
|
2022
Q2 | $868M | Buy |
8,904,474
+127,016
| +1% | +$11.7M | 0.02% | 609 |
|
|
2022
Q1 | $823M | Sell |
8,777,458
-10,533
| -0.1% | -$893K | 0.02% | 697 |
|
|
2021
Q4 | $748M | Sell |
8,787,991
-100,479
| -1% | -$9.24M | 0.02% | 775 |
|
|
2021
Q3 | $852M | Sell |
8,888,470
-96,151
| -1% | -$9.08M | 0.02% | 706 |
|
|
2021
Q2 | $874M | Buy |
8,984,621
+155,346
| +2% | +$14.9M | 0.02% | 702 |
|
|
2021
Q1 | $859M | Buy |
8,829,275
+492,010
| +6% | +$51.6M | 0.02% | 682 |
|
|
2020
Q4 | $799M | Buy |
8,337,265
+175,732
| +2% | +$17M | 0.02% | 668 |
|
|
2020
Q3 | $785M | Sell |
8,161,533
-317,806
| -4% | -$36.8M | 0.03% | 593 |
|
|
2020
Q2 | $1.03B | Sell |
8,479,339
-24,349
| -0.3% | -$2.69M | 0.04% | 489 |
|
|
2020
Q1 | $736M | Buy |
8,503,688
+186,791
| +2% | +$18.3M | 0.03% | 526 |
|
|
2019
Q4 | $894M | Buy |
8,316,897
+100,511
| +1% | +$10.5M | 0.03% | 578 |
|
|
2019
Q3 | $740M | Buy |
8,216,386
+99,017
| +1% | +$9.25M | 0.03% | 625 |
|
|
2019
Q2 | $685M | Sell |
8,117,369
-38,488
| -0.5% | -$3.16M | 0.03% | 663 |
|
|
2019
Q1 | $719M | Buy |
8,155,857
+76,039
| +0.9% | +$6.36M | 0.03% | 615 |
|
|
2018
Q4 | $577M | Buy |
8,079,818
+307,582
| +4% | +$29.5M | 0.03% | 643 |
|
|
2018
Q3 | $956M | Buy |
7,772,236
+204,065
| +3% | +$23.2M | 0.04% | 537 |
|
|
2018
Q2 | $743M | Buy |
7,568,171
+257,865
| +4% | +$23.1M | 0.03% | 598 |
|
|
2018
Q1 | $606M | Buy |
7,310,306
+184,913
| +3% | +$15.6M | 0.03% | 653 |
|
|
2017
Q4 | $553M | Buy |
7,125,393
+101,951
| +1% | +$6.95M | 0.02% | 707 |
|
|
2017
Q3 | $430M | Buy |
7,023,442
+101,148
| +1% | +$5.34M | 0.02% | 786 |
|
|
2017
Q2 | $318M | Buy |
6,922,294
+186,329
| +3% | +$9.04M | 0.02% | 946 |
|
|
2017
Q1 | $292M | Buy |
6,735,965
+293,755
| +5% | +$12.6M | 0.02% | 979 |
|
|
2016
Q4 | $249M | Buy |
6,442,210
+153,953
| +2% | +$6.97M | 0.01% | 1030 |
|
|
2016
Q3 | $318M | Buy |
6,288,257
+208,888
| +3% | +$10.4M | 0.02% | 824 |
|
|
2016
Q2 | $276M | Sell |
6,079,369
-7,353
| -0.1% | -$339K | 0.02% | 868 |
|
|
2016
Q1 | $241M | Buy |
6,086,722
+148,691
| +3% | +$5.9M | 0.02% | 922 |
|
|
2015
Q4 | $336M | Buy |
5,938,031
+175,693
| +3% | +$8.93M | 0.02% | 741 |
|
|
2015
Q3 | $229M | Buy |
5,762,338
+399,910
| +7% | +$19.3M | 0.02% | 914 |
|
|
2015
Q2 | $256M | Buy |
5,362,428
+1,419,573
| +36% | +$60.2M | 0.02% | 904 |
|
|
2015
Q1 | $157M | Buy |
3,942,855
+1,581,276
| +67% | +$56.6M | 0.01% | 1183 |
|
|
2014
Q4 | $52.8M | Buy |
2,361,579
+77,743
| +3% | +$1.47M | ﹤0.01% | 1806 |
|
|
2014
Q3 | $35.8M | Buy |
2,283,836
+68,679
| +3% | +$1.03M | ﹤0.01% | 1963 |
|
|
2014
Q2 | $32.9M | Sell |
2,215,157
-5,985
| -0.3% | -$84.5K | ﹤0.01% | 2033 |
|
|
2014
Q1 | $35.8M | Buy |
2,221,142
+334,323
| +18% | +$5.72M | ﹤0.01% | 1973 |
|
|
2013
Q4 | $17.6M | Buy |
1,886,819
+59,305
| +3% | +$579K | ﹤0.01% | 2213 |
|
|
2013
Q3 | $20.7M | Buy |
1,827,514
+19,130
| +1% | +$263K | ﹤0.01% | 2098 |
|
|
2013
Q2 | $24.2M | Buy |
+1,808,384
| New | +$22.2M | ﹤0.01% | 2003 |
|
Other funds holding NBIX
BG
Vanguard Group's NBIX Position: Q4 2025 in Review
Vanguard Group reduced its Neurocrine Biosciences (NBIX) stake by 0.06% in Q4 2025, selling an estimated $907K and leaving 9,700,301 shares worth $1.38B. The position accounts for 0.02% of the portfolio, ranked #595.
Vanguard Group first reported a position in NBIX in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.38B in Q2 2024. 730 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.
- Vanguard Group held 9,700,301 shares of Neurocrine Biosciences worth $1.38B as of Q4 2025.
- Vanguard Group sold 6,258 Neurocrine Biosciences shares in Q4 2025, an estimated $907K.
- Neurocrine Biosciences made up 0.02% of Vanguard Group's portfolio in Q4 2025, its #595 holding.
- Vanguard Group first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Neurocrine Biosciences position peaked at $1.38B in Q2 2024.
- 730 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.